GlaxoSmithKline S.A.E (EGX:BIOC)

Egypt · Delayed Price · Currency is EGP

64.26

-0.85 (-1.31%)

At close: Apr 15, 2026

73.58% (1Y)

Market Cap	5.37B +65.3%
Revenue (ttm)	3.73B +24.7%
Net Income	213.23M +22.6%
EPS	2.55 +22.6%
Shares Out	83.51M
PE Ratio	25.17
Forward PE	n/a
Dividend	1.00 (1.54%)
Ex-Dividend Date	Jan 12, 2026

Volume	37,771
Average Volume	52,671
Open	65.11
Previous Close	65.11
Day's Range	64.11 - 66.45
52-Week Range	34.34 - 81.50
Beta	0.76
RSI	60.79
Earnings Date	May 18, 2026

About GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E engages in production of pharmaceutical chemicals. The company is involved in manufacture of general and specialty medicines, and vaccines. GlaxoSmithKline S.A.E was founded in 1981 and is based in New Cairo, Egypt. GlaxoSmithKline S.A.E operates as a subsidiary of Glaxo Group Limited. [Read more]

Industry Pharmaceutical Preparations

Founded 1981

Employees 800

Stock Exchange Egyptian Stock Exchange

Ticker Symbol BIOC

Full Company Profile

Financial Performance

In 2025, GlaxoSmithKline S.A.E's revenue was 3.73 billion, an increase of 24.73% compared to the previous year's 2.99 billion. Earnings were 213.23 million, an increase of 22.56%.

Financial Statements